Systemic lupus erythematosus, or lupus, is a complex autoimmune disease in which the immune system mistakenly attacks healthy ...

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of ...

Patients whose autoimmune disorders such as lupus were initially dismissed by doctors as psychosomatic show long-lasting ...

Lupus is an autoimmune disease where the body’s immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new ...

For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20% of patients and associated factors include younger age, prednisone treatment, ...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a complete renal ...

Comparing 2,022 lupus patients with 20,019 people from the general population, incidence rate ratios for general practice (GP ...

Uniklinikum Erlangen at Friedrich-Alexander-Universität Erlangen-Nürnberg has successfully treated more than 45 people with autoimmune diseases using ...

Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment ...

“The FDA’s sBLA acceptance for Gazyva recognizes the need to provide a more effective treatment option for people living with this devastating disease.” “Lupus nephritis is a debilitating ...